The global diabetic nephropathy market is experiencing a substantial growth because of the growth in the occurrences of obesity & diabetes in various regions across the globe. In addition to this, rising R&D investment levels in drug discoveries and development by major companies are also said to drive the growth of the overall market. The global market is estimated to grow at a CAGR of 5 % over the forecast period (from 2013 to 2018).
For further inquiries, about – Diabetic Nephropathy Market Analysis, Size, Share, Growth, Trends and Forecast 2013 – 2018, click on this link – http://www.radiantinsights.com/research/global-diabetic-nephropathy-market-2014-2018
Diabetic nephropathy, also known as diabetic kidney disease, is a disorder of the kidney glomerulus. When diabetes harms kidneys, that contain a number of small blood vessel clusters, glomeruli, that filter the blood wastes, it results in diabetic nephropathy. This kidney disease is primarily characterized by macroalbuminuria, in which the presence of albumin in the urine goes up to 300 mg in one day.
Any severe damages may result in an irreversible End Stage Renal Disease (ESRD) or kidney failure, needing a kidney transplant or dialysis. There are no symptoms or signs in the early stage of diabetic nephropathy; however, major signs in the later stages include high blood pressure, increased albumin emission in urine, leg & ankle swelling, nausea, morning weakness, anemia, vomiting, etc.
Browse All Reports of This Category @ http://www.radiantinsights.com/catalog/pharmaceutical
The treatments to limit the development of diabetic nephropathy include blood pressure control and glycemic control. Moreover, the Disease Modifying Therapies (DMT) that utilizes Angiotensin II Receptor Blockers (ARBs) and Angiotensin-Converting Enzyme (ACE) inhibitors are also used for the diabetic nephropathy treatment. Disease Modifying Therapies is the biggest and popular mode of treatment, whereas ACE inhibitors are the fastest-growing DMT of diabetic nephropathy.
Geographically, the North America region is the biggest regional diabetic nephropathy market, followed by Europe. Several other fastest-growing regional markets include Japan & China. This is mainly because of a rise in the diabetic population base and rising occurrences of different kidney diseases in these regions.
Request a Free Sample Copy of this Report @ http://www.radiantinsights.com/research/global-diabetic-nephropathy-market-2014-2018/request-sample
The growing patient awareness about kidney-related diseases and diabetes is also said to boost the global market growth. However, on the other hand, strict regulatory policies, longer approval process for drugs, and lacking diabetic nephropathy therapeutic management are the major concerns for the global market. Rising usage of combination therapy is the most recent trend observed in the market.
Some of the major players operating in the diabetic nephropathy market include Sanofi S. A., Pfizer, Inc., Novartis International AG, Merck & Co., Inc., Abbott Laboratories.
Related Reports by Radiant Insights:
• Pepsin Industry
• Europe Non-Gelatin Empty Capsules Market
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their Market research and business intelligence requirements. It assist and facilitate organizations and individuals procure Market research reports, helping them in the decision making process. The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro Markets. In addition to over extensive database of reports, experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
Country: United States